Table 1

Recommendations of professional organisations in terms of communicating about prostate screening

Items included in recommendation and guidanceProfessional organisation
PCFA/CCANHMRCRACGPUSANZNICENHS/PHEUSPSTFACSNCIAUA
Is GP advised about whether to raise the topic with men if men do not raise it first?
Is a decision aid recommended?
Is a decision aid provided?
Is IDM* recommended?
Is SDM† recommended?
Is guideline accompanied by a clinician information sheet?‡
Is guideline accompanied by a patient information sheet?§
Does guideline recommend clinician to share their own PSA screening decision?
Consider medico-legal responsibilities?
  • *The patient is presented with all the information pertinent to making a decision and then assumes final authority for the decision.30

  • †The patient is provided with all the relevant information and works with the healthcare provider to reach a decision that reflects the health preference of the patient.30

  • ‡A clinician information sheet is a fact sheet summarising the evidence of benefits, limitations and associated risks of prostate screening to help clinicians to accurately inform men.

  • §A patient information sheet is a fact sheet outlining the benefits, limitations and associated risks of having a PSA test for prostate cancer risk.

  • ACS, American Cancer Society; AUA, American Urological Association; GP, general practitioner; IDM, informed decision making; NCI, National Cancer Institute of the National Institutes of Health; NHMRC, National Health and Medical Research Council; NHS/PHE, National Health Service/Public Health England; NICE,  National Institute for Health and Care Excellence; PCFA/CCA, Prostate Cancer Foundation of Australia/Cancer Council Australia; PSA, prostate-specific antigen; RACGP, Royal Australian College of General Practitioners; SDM, shared decision making; USANZ, Urological Society of Australia and New Zealand; USPSTF, United States Preventive Services Task Force.